Scott Carpenter, 50, serves as our Chief Operating Officer. Mr. Carpenter is the Chief Operating Officer of Alpha Wave Global. He is responsible for the non-investment side of the business. He was a founding member of the firm when he joined at the beginning of 2012. Prior to that, Mr. Carpenter was the Global Head of Operations at CQS in London for eight years where he held a variety of responsibilities including Company Secretary for the CQS Management entities. Prior to joining CQS in 2004, Scott worked for Credit Suisse for 10 years in a variety of operational management roles in London, New York, Brisbane, Sydney, Wellington and Singapore.
Matthew Corey, 37, serves as our Chief Financial Officer. Mr. Corey is the Chief Financial Officer of Alpha Wave Global. Prior to that, Mr. Corey worked for Gruss Capital Management for 10 years in a variety of roles including Chief Financial Officer, Controller and Senior Accountant. Mr. Corey worked on all aspects of fund accounting, management accounting, tax, operations, treasury and investor reporting at Gruss Capital Management. Mr. Corey started his career as an auditor with Rothstein Kass from 2006 to 2009, where he conducted a variety of private company audits and prepared private company tax returns. Mr. Corey graduated from Lehigh University with a Bachelor of Science in Accounting and completed a Master of Science in Jurisprudence from the Seton Hall School of Law. Mr. Corey is a Certified Public Accountant licensed in New York.
David A. Sinclair, Ph.D, A.O., 53, serves on our board of directors and is our Co-Chairman. Dr. Sinclair is a Professor in the Department of Genetics, co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, and a NY Times bestselling author. He is renowned for his work on understanding why we age and how to slow and reverse its effects. Dr. Sinclair is co-founder of several biotechnology companies, including Sirtris Pharma (acquired by GSK), Genocea, Cohbar, Life Biosciences, MetroBiotech, ArcBio, and Liberty Biosecurity, and serves on the boards of several others. He has received over 25 awards and honors including The Merck Prize, The ASBMB Medal, The Genzyme Award, TIME100’s “most influential people in the world”, and TIME’s “Top 50 in healthcare.” He is an inventor on approximately 50 patents and co-author more than 200 scientific papers. Dr. Sinclair obtained his Ph.D. in Molecular Genetics from the University of New South Wales, Sydney and worked as a postdoctoral researcher at the Massachusetts Institute of Technology before being hired as an Assistant Professor at Harvard Medical School. In 2018, he became an Officer of the Order of Australia (AO).
Peter Attia, 48, serves on our board of directors and is our Co-Chairman. Dr. Attia is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (how long you live), while simultaneously improving healthspan (the quality of your life). Dr. Attia is the co-founder and Chief Medical Officer of the fasting app Zero. Dr. Attia co-founded and served as the first President of Nutrition Science Initiative in 2012. He is an advisor to, and/ or investor in, the companies Virta Health, Hu Kitchen, Oura Health Oy, Magic Spoon Cereal, Inevitable Ventures, Salutoceuticals, Dexcom, Kia Hawaii, and Supercast. Dr. Attia earned his M.D. from Stanford University and holds a B.Sc. in mechanical engineering and applied mathematics. Dr. Attia trained for five years at the Johns Hopkins Hospital in general surgery, where he was the recipient of several awards, including resident of the year. He spent two years at NIH as a surgical oncology fellow at the National Cancer Institute where his research focused on immune-based therapies for melanoma.
Jonathan Christodoro, 45, serves on our board of directors. Mr. Christodoro has served as the Chief Investment Officer and President at Patriot Global Management, LP since 2018. Prior to that, Mr. Christodoro previously served as a Managing Director of Icahn Capital LP, the entity through which Carl Icahn manages investment funds. Prior to joining Icahn Capital, Mr. Christodoro served in various investment and research roles. Mr. Christodoro began his career as an investment banking analyst at Morgan Stanley, where he focused on merger and acquisition transactions across a variety of industries. Mr. Christodoro currently serves as a director on the board of PayPal and Pioneer Merger Corp. He was previously a board member of eBay, Lyft, Herbalife, Xerox, Sandridge Energy, Hologic, Talisman Energy, Enzon Pharmaceuticals, American Railcar Industries and Cheniere Energy. Mr. Christodoro received an M.P.H. from the Harvard T.H. Chan School of Public Health, an M.B.A. from the University of Pennsylvania's Wharton School of Business with Distinction, and a B.S. in Applied Economics and Management Magna Cum Laude with Honors Distinction in Research from Cornell University. He also served in the United States Marine Corps.
Number and Terms of Office of Officers and Directors
Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of shareholders) serving a three-year term. The term of office of the first class of directors, consisting of Rick Gerson, will expire at our first annual meeting of shareholders. The term of office of the second class of directors, consisting of Christian Angermayer and Jonathan Christodoro, will expire at our second annual